Hikma confirms full year guidance

14th May 2009 07:58

Pharmaceutical firm Hikma said it maintains its guidance on delivering full-year revenue growth of 10-15% and gross margin improvement of 1-2%. The group said it is on track to deliver Branded sales growth in line with expectations for the full year, while the Generics business is performing ahead of forecasts. In the global Injectables unit, the MENA region continues to offer excellent growth opportunities. The business in Europe is steady, despite the tough competitive environment. In the US, Injectables sales will be lower in the first half compared to the same period last year, but this will be compensated for in the second half by new business already awarded.